• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).含拉替拉韦方案治疗的 HIV-1 感染女性生殖道内拉替拉韦浓度（DIVA 01 研究）。
Antimicrob Agents Chemother. 2011 Jun;55(6):3018-21. doi: 10.1128/AAC.01460-10. Epub 2011 Mar 28.
2
Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study.接受含依曲韦林的抗逆转录病毒治疗的 HIV-1 感染妇女的宫颈阴道部位的依曲韦林浓度：DIVA 02 研究。
Antimicrob Agents Chemother. 2012 Jul;56(7):4018-20. doi: 10.1128/AAC.06474-11. Epub 2012 Apr 23.
3
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.接受包含这些抗逆转录病毒药物的治疗方案的 HIV 阳性患者的女性和男性生殖道中总游离型马拉维若、雷特格韦和利匹韦林的穿透率和抗病毒疗效。
J Antimicrob Chemother. 2017 Nov 1;72(11):3167-3171. doi: 10.1093/jac/dkx275.
4
Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.HIV感染和绝经状态对血液及生殖道中raltegravir药代动力学的影响。
Antivir Ther. 2015;20(8):795-803. doi: 10.3851/IMP2968. Epub 2015 Jun 3.
5
Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women.HIV-1感染女性生殖道中的蛋白酶抑制剂和非核苷类逆转录酶抑制剂浓度。
J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1577-80. doi: 10.1097/00126334-200412150-00008.
6
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.马拉维若在HIV阴性女性的宫颈阴道液和阴道组织中聚集。
J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):546-53. doi: 10.1097/QAI.0b013e3181ae69c5.
7
Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.宫颈阴道液和直肠液作为抗逆转录病毒药物组织浓度的替代标志物：对临床试验设计的意义。
J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):498-506. doi: 10.1097/QAI.0000000000000996.
8
High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.精液中高浓度雷替拉韦：EASIER-ANRS 138 试验的亚研究结果。
Antimicrob Agents Chemother. 2010 Feb;54(2):937-9. doi: 10.1128/AAC.01261-09. Epub 2009 Dec 7.
9
Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.在CAPRISA 004试验中，生殖器替诺福韦浓度与预防HIV感染相关：坚持用药对杀微生物剂有效性的重要性。
J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):264-9. doi: 10.1097/QAI.0000000000000607.
10
Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum.妊娠和产后期间女性的利匹韦林血浆和宫颈阴道浓度。
J Acquir Immune Defic Syndr. 2018 Jul 1;78(3):308-313. doi: 10.1097/QAI.0000000000001677.

引用本文的文献

1
Novel Perspectives on the Design and Development of a Long-Acting Subcutaneous Raltegravir Injection for Treatment of HIV-In Vitro and In Vivo Evaluation.用于治疗HIV的长效皮下注射拉替拉韦设计与开发的新视角——体外和体内评价
Pharmaceutics. 2023 May 18;15(5):1530. doi: 10.3390/pharmaceutics15051530.
2
Relationship between raltegravir trough plasma concentration and virologic response and the impact of therapeutic drug monitoring during pregnancy.拉替拉韦血药浓度与病毒学应答的关系及妊娠期治疗药物监测的影响。
Int J STD AIDS. 2023 Mar;34(3):175-182. doi: 10.1177/09564624221144489. Epub 2022 Dec 18.
3
A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.整合酶抑制剂拉替拉韦的长效制剂可保护人源化BLT小鼠免受反复高剂量阴道HIV攻击。
J Antimicrob Chemother. 2016 Jun;71(6):1586-96. doi: 10.1093/jac/dkw042. Epub 2016 Mar 21.
4
Barriers to a cure for HIV in women.女性艾滋病治愈的障碍。
J Int AIDS Soc. 2016 Feb 18;19(1):20706. doi: 10.7448/IAS.19.1.20706. eCollection 2016.
5
Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.雷特格韦在体外人胎盘小叶灌注模型中的双向转运
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3112-4. doi: 10.1128/AAC.00007-16. Print 2016 May.
6
Mucosal tissue pharmacokinetics of the integrase inhibitor raltegravir in a humanized mouse model: Implications for HIV pre-exposure prophylaxis.整合酶抑制剂拉替拉韦在人源化小鼠模型中的黏膜组织药代动力学：对HIV暴露前预防的意义
Virology. 2016 Feb;489:173-8. doi: 10.1016/j.virol.2015.12.014. Epub 2016 Jan 6.
7
Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.与HIV性传播相关的组织和细胞中的药物转运体：对药物递送的影响。
J Control Release. 2015 Dec 10;219:681-696. doi: 10.1016/j.jconrel.2015.08.018. Epub 2015 Aug 13.
8
Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.在接受拉替拉韦与增强型阿扎那韦治疗方案的HIV-1感染女性中，生殖器药物浓度与宫颈细胞免疫激活及重建之间的关系
AIDS Res Hum Retroviruses. 2015 Oct;31(10):1015-22. doi: 10.1089/AID.2014.0301. Epub 2015 Jun 10.
9
Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.HIV感染和绝经状态对血液及生殖道中raltegravir药代动力学的影响。
Antivir Ther. 2015;20(8):795-803. doi: 10.3851/IMP2968. Epub 2015 Jun 3.
10
Pharmacokinetics of antiretrovirals in mucosal tissue.抗逆转录病毒药物在黏膜组织中的药代动力学。
Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):893-905. doi: 10.1517/17425255.2015.1027682. Epub 2015 Mar 22.

本文引用的文献

1
Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.每日两次服用 600/100 毫克达芦那韦/利托那韦联合两种核苷类逆转录酶抑制剂或单药治疗的患者，其 HIV-1 精液间歇性低频率排出。
Antimicrob Agents Chemother. 2010 Nov;54(11):4910-3. doi: 10.1128/AAC.00725-10. Epub 2010 Aug 16.
2
High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.精液中高浓度雷替拉韦：EASIER-ANRS 138 试验的亚研究结果。
Antimicrob Agents Chemother. 2010 Feb;54(2):937-9. doi: 10.1128/AAC.01261-09. Epub 2009 Dec 7.
3
Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy.在高效抗逆转录病毒疗法有效的情况下测定精液中1型人类免疫缺陷病毒载量。
J Clin Microbiol. 2009 Sep;47(9):2883-7. doi: 10.1128/JCM.02131-08. Epub 2009 Jul 29.
4
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.马拉维若在HIV阴性女性的宫颈阴道液和阴道组织中聚集。
J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):546-53. doi: 10.1097/QAI.0b013e3181ae69c5.
5
Effects of omeprazole on plasma levels of raltegravir.奥美拉唑对拉替拉韦血浆水平的影响。
Clin Infect Dis. 2009 Feb 15;48(4):489-92. doi: 10.1086/596503.
6
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.HIV-2整合酶基因多态性及HIV-2临床分离株在体外对整合酶抑制剂拉替拉韦和埃替格韦的表型敏感性
J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20.
7
Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.在单独使用一线洛匹那韦/利托那韦或联合齐多夫定/拉米夫定治疗1年后，男性生殖道中未检测到HIV-1脱落。
J Antimicrob Chemother. 2008 Jun;61(6):1344-7. doi: 10.1093/jac/dkn098. Epub 2008 Mar 13.
8
Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.接受长期高效抗逆转录病毒治疗的HIV感染女性生殖道中的抗逆转录病毒药物浓度和HIV RNA
Clin Infect Dis. 2008 Mar 1;46(5):719-25. doi: 10.1086/527387.
9
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.女性生殖道中的抗逆转录病毒药物暴露：对口服暴露前和暴露后预防的影响。
AIDS. 2007 Sep 12;21(14):1899-907. doi: 10.1097/QAD.0b013e328270385a.
10
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.健康受试者单次及多次服用拉替拉韦后的安全性、耐受性和药代动力学。
Clin Pharmacol Ther. 2008 Feb;83(2):293-9. doi: 10.1038/sj.clpt.6100281. Epub 2007 Aug 22.

含拉替拉韦方案治疗的 HIV-1 感染女性生殖道内拉替拉韦浓度（DIVA 01 研究）。

Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).

机构信息

Department of Infectious Diseases, Pitié-Salpêtrière Hospital, Boulevard de l'Hôpital, Paris 75013, France.

出版信息

Antimicrob Agents Chemother. 2011 Jun;55(6):3018-21. doi: 10.1128/AAC.01460-10. Epub 2011 Mar 28.

DOI:10.1128/AAC.01460-10
PMID:21444705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3101453/
Abstract

We studied the penetration of raltegravir and HIV shedding in the genital tract among 14 HIV-1-infected women receiving a raltegravir-containing regimen who had <40 copies/ml blood plasma (BP) HIV RNA. None of the cervicovaginal fluid (CVF) samples showed detectable HIV RNA. Median raltegravir concentrations were 235 ng/ml in BP and 93 ng/ml in CVF, with a CVF/BP ratio of approximately 2.3. This good penetration of raltegravir may contribute to the control of viral replication in the female genital tract.

摘要

我们研究了 14 名接受含拉替拉韦方案治疗且血液血浆（BP）HIV RNA<40 拷贝/ml 的 HIV-1 感染女性的生殖道中拉替拉韦的渗透和 HIV 脱落情况。没有宫颈阴道分泌物（CVF）样本显示可检测到的 HIV RNA。BP 中的中位数拉替拉韦浓度为 235ng/ml，CVF 中的中位数为 93ng/ml，CVF/BP 比值约为 2.3。拉替拉韦的这种良好渗透可能有助于控制女性生殖道中的病毒复制。